Northeast Oncology Group

Northeast Oncology Group
Name	Northeast Oncology Group
Abbreviation	NEOG (historical)
Formation	1960s
Dissolution	1990s (merged)
Purpose	Clinical oncology research, multicenter trials, cooperative group
Headquarters	Boston, Massachusetts
Region served	United States, Canada
Leader title	Director
Parent organization	Cancer and Leukemia Group B (post-merger affiliates)

Northeast Oncology Group was a multicenter cooperative clinical trials consortium focused on cancer research in the northeastern United States and Canada. Founded in the mid-20th century, the group conducted phase II and phase III trials in medical oncology, surgical oncology, and radiation oncology, collaborating with academic medical centers, community hospitals, and government agencies. NEOG played a role in protocol development, investigator training, and patient accrual that influenced later cooperative groups and national cancer policy.

History

The organization emerged amid regional initiatives following pivotal developments such as the National Cancer Act of 1971, institutional expansion at Massachusetts General Hospital, and growing cooperative efforts similar to the Southwest Oncology Group and Eastern Cooperative Oncology Group. Early leaders included investigators affiliated with Dana–Farber Cancer Institute, Tufts Medical Center, and Brigham and Women's Hospital, who coordinated multicenter trials inspired by methodology from the National Institutes of Health and the National Cancer Institute. Over decades, NEOG adapted protocols to incorporate advances from investigators at Memorial Sloan Kettering Cancer Center, Yale School of Medicine, University of Pennsylvania, and Johns Hopkins Hospital. By the 1990s, structural realignments and consolidation among cooperative groups, driven by initiatives from the Institute of Medicine and the NCI Cooperative Groups Program, resulted in mergers or absorption into larger consortia comparable to transitions experienced by Cancer and Leukemia Group B and North Central Cancer Treatment Group.

Organizational structure and governance

Governance mirrored models used by National Cancer Institute cooperative consortia, with an executive committee, protocol review panels, and data monitoring committees that included representatives from institutions such as Columbia University Irving Medical Center, Brown University, University of Rochester Medical Center, and Montefiore Medical Center. Scientific leadership often included chairs drawn from departments at Harvard Medical School, Icahn School of Medicine at Mount Sinai, Roswell Park Comprehensive Cancer Center, and Barcelona Institute for Global Health-style international affiliates (informal collaborations). Regulatory oversight engaged ethics reviewers associated with institutional review boards at Cornell University, Syracuse University, and Northeastern University partner hospitals. Administrative functions liaised with grant officers at Rockefeller University and legal counsel experienced with federal policy from offices parallel to those at Georgetown University.

Research programs and clinical trials

NEOG developed trials across malignancies informed by research paradigms established at Stanford University School of Medicine, University of California, San Francisco, Mayo Clinic, and Cleveland Clinic. Oncology programs targeted breast cancer, lung cancer, colorectal cancer, leukemia, lymphoma, and sarcoma, using endpoints and statistical designs influenced by biostatisticians from Johns Hopkins Bloomberg School of Public Health, Harvard T.H. Chan School of Public Health, and Columbia University Mailman School of Public Health. Notable trial types included adjuvant chemotherapy studies parallel to those at Sloan Kettering, neoadjuvant protocols similar to work at University of Chicago, and multimodality trials reflecting collaborations with departments at University of Pittsburgh Medical Center and Vanderbilt University Medical Center. Data management and randomization practices aligned with standards from Food and Drug Administration guidance and monitoring comparable to procedures at Fred Hutchinson Cancer Research Center.

Collaborations and partnerships

NEOG partnered with academic centers, community hospitals, industry sponsors, and governmental bodies. Academic collaborators included Brown University Warren Alpert Medical School, Boston University School of Medicine, Rutgers Robert Wood Johnson Medical School, and University of Connecticut School of Medicine. Partnerships spanned pharmaceutical companies similar to Eli Lilly and Company, Merck & Co., and Pfizer for investigational agents, and contract research organizations patterned after those working with GlaxoSmithKline. International academic links drew on networks resembling ties between McGill University and University of Toronto. Cooperative relationships extended to advocacy organizations like American Cancer Society and policy institutions such as American Society of Clinical Oncology.

Funding and grants

Funding sources paralleled those common to cooperative oncology groups: peer-reviewed grants from the National Cancer Institute, supplemental awards from the National Institutes of Health, philanthropic contributions from foundations in the model of the Dana-Farber Cancer Institute donors, and corporate clinical trial support similar to arrangements with Roche. Financial oversight utilized grant management expertise akin to that at Johns Hopkins University and audit practices consistent with standards from Health Resources and Services Administration-style agencies. Pilot studies often received seed funding comparable to awards from the American Association for Cancer Research and institutional funds administered through mechanisms at Yale Cancer Center.

Impact and notable achievements

NEOG influenced practice patterns and clinical trial conduct across its region, contributing to evidence that informed standards developed by bodies like National Comprehensive Cancer Network and American Society of Clinical Oncology. Its investigators published findings in journals similar to Journal of Clinical Oncology, The Lancet Oncology, and Cancer Research, and presented at conferences such as ASCO Annual Meeting and European Society for Medical Oncology Congress. Alumni from NEOG offices went on to leadership roles at institutions including Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Mayo Clinic, shaping subsequent cooperative research efforts. Legacy outcomes include protocol templates, data-sharing practices, and investigator training programs that influenced successor consortia comparable to Alliance for Clinical Trials in Oncology and SWOG.

Category:Oncology research organizations